By proceeding, you agree to our Terms of Use and Privacy Policy.
Zeon Specialty Materials, Inc. is a wholly owned subsidiary of ZEON CORPORATION of Tokyo, Japan, a world leader in specialty elastomers, polymers and specialty chemicals.
12-13 January 2022
SMi is a highly professional, global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. Part of the SAE Media Group, SMi researches, creates and delivers events in the Defence, Security, Energ
Event Ended
Virtual
Paid
06-08 March 2023
For almost 3 decades, the Molecular & Precision Med TRI-CON has served as the leading international meeting place for the diagnostics and precision medicine community.
Hybrid
San Diego
24-25 April 2023
The 10th annual Pre-Filled Syringes East Coast conference is back with a diverse gathering of experts in drug delivery, medical devices, and pre-filled syringes. They will exchange insights on the latest trends and innovative solutions to address the
USA
Boston
21-22 August 2023
The 8th annual Liquid Biopsy for Disease Management: From Discovery to Clinical Use conference will review new liquid biopsies coming on the market that have increased sensitivity and are robust enough for clinical applications for measuring treatmen
Washington, DC
The point-of-care industry is poised for tremendous growth and is fueled by both the explosion of enabling technologies as well as the huge need for disruption in the medical sector as consumers demand flexibility and access to testing as well as fas
Development of companion diagnostics shows no signs of slowing down anytime soon. As the field continues to grow, it is critical that the surrounding landscape progresses with it. Partnerships between pharmaceutical and diagnostic companies can lead
22-23 August 2023
The increase in testing and demands of the COVID-19 pandemic has spurred tremendous innovation for infectious disease testing platforms that reduce time, cost, and offer greater access than ever before. At the 15th Annual Advanced Diagnostics for Inf
As diagnostics become increasingly complex, coverage and reimbursement come to the forefront of challenges that diagnostic companies face. Deep understanding of how policy is developed and implemented and how policy will change over time will provide
Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that there are no screening tests available for the majority of cancers, and far too often cancer is only detected onc
Within the last few years, we saw a seismic global shift in the acceptance and availability of point-of-care and home-based testing, bolstered by a heightened interest in and capability for decentralized processes. Healthcare systems and providers we